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Methods for mapping facilitators and hindrances: Focus group
interviews with main stakeholders and review of existing
documentation.
Implementation Strategy: The Swedish model was chosen for
implementation in Iceland, with the aim of avoiding to reinvent
the wheel for the small and sparsely populated country. It is
assumed that disease pattern is similar in the two countries, and
that population pyramids are sufﬁciently similar for the purpose
of applying Swedish cost-effectiveness data in Iceland. The best
way to use the Swedish model would be to adapt the cost-
effectiveness modeling to the situation in Iceland, i.e. to get ready
reports/models from Sweden, with the possibility of recalculating
the cost-effectiveness on the basis of Icelandic data.
Results: The focus group interviews showed that change man-
agement needs to be applied as regards the civil servants, as they
show a reluctant attitude towards implementing this change. On
the contrary the focus group interviews revealed that the drug
industry has a more positive view of the change, probably inﬂu-
enced by the seemingly good cooperation between the drug
industry and the Pharmaceutical Beneﬁts Board in Sweden
(LFN). Based on the results the health ministers of Iceland and
Sweden signed in June 2008 letter of intent stating that the
Government of Iceland and the Government of Sweden declare
their intention to strengthen and broaden mutual co-operation in
the ﬁeld of pricing and reimbursement of pharmaceuticals. The
Icelandic Medicine Pricing and Reimbursement Committee and
the Pharmaceutical Beneﬁts Board in Sweden (LFN) have started
collaboration on possible dual application on price and reim-
bursements and revaluation of pharmaceutical groups for
reimbursements.
Lessons Learned: Small markets in Europe are facing various
issues regarding pricing and reimbursements of pharmaceuticals
and evaluation from a cost-effectiveness perspective. For reim-
bursement authorities in smaller markets cooperation with lager
organizations is important. The Icelandic Medicine Pricing and
Reimbursement Committee and the Pharmaceutical Beneﬁts
Board in Sweden (LFN) will be starting a pilot project offering
the industry a dual application for price and reimbursement in
Iceland and Sweden. This pilot project will reveal the obstacles
encountered in dual application and how cost effectiveness
reports based on Swedish settings apply to Icelandic settings. If
Icelandic authorities cannot use the reports accompanying appli-
cations in Sweden, an attempt could be made at ﬁnding a con-
stant that could be used as a multiplier for all Swedish cost items,
or results from Sweden could be used without evaluating to what
extent they apply to Iceland, with all the imprecision inherent in
that method.
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PHARMACOECONOMIC APPLICATIONS IN FORMULARY
MANAGEMENT: BUDGET IMPACT ANALYSIS OF PACLITAXEL
PROTEIN-BOUND AT A MAJOR CANCER CENTER
Miller LA, Lau J, Lal LS,Arbuckle R
University of Texas—MD Anderson Cancer Center, Houston,TX,
USA
OBJECTIVES: Develop a budget impact analysis to present to the
Pharmacy and Therapeutics (P&T) Committee for approval of
paclitaxel protein-bound (paclitaxel-PB) to the institution’s For-
mulary formetastatic breast cancer (MBC). A post-approval study
was performed to assess the accuracy and validity of our model.
METHODS: A pre-approval annual budget impact model for
paclitaxel-PB was developed, and presented to P&T in 2006.
Assumptions regarding paclitaxel-PB’s number of doses per cycle
and median number of cycles per patient were estimated from
published clinical trials and clinicians estimated use. In 2007, a
post-approval economic analysis was conducted to assess the
actual annual budget impact of paclitaxel-PB. All costs were
adjusted to 2007 dollars. RESULTS: Paclitaxel-PB was FDA-
approved forMBC in January 2005. InMay 2006 a budget impact
model was developed for an institutional population of 46 MBC
patients; the $722,935 estimate was presented to the P&T. In
September of 2007, we reviewed all use (excluding investiga-
tional) of paclitaxel-PB from June 2006 through May 2007.
During this time period, we treated 131 patients; of these, 76
(58%) were for MBC, 47 (36%) for metastatic melanoma and
8 (6%) for other indications. We also reviewed charge and
reimbursement data for paclitaxel-PB from June to December
2006. For the MBC population, we had a positive margin, and
reimbursement to charge ratio was 59%. When all indications
were included, the overall reimbursement to charge ratio for
paclitaxel-PB was 56%. Actual budget impact was $757,502.
CONCLUSIONS: Differences were noted between the two
studies. Our pre-approval model included only MBC, and fewer
patients than were actually treated. Although we found more
patients on paclitaxel-PB for both FDA-approved and non FDA-
approved indications, the budget impact was essentially the same.
The major factors driving the difference between pre and post-
approval were actual cost per mg and average dose per patient.
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OBJECTIVES: As mentioned in the ISPOR guidelines for budget
impact analysis, estimating the size of the target population and
possible patient subgroups over time is critical for the determi-
nation of the budget impact. The goal of this study was to
estimate the number of patients with bone metastases (BM)
subsequent to breast cancer (BC) from 1992 to 2020 in the UK.
METHODS: A demographic model was developed to assess the
size of the at-risk population. BC incidence rates were obtained
from the Ofﬁce for National Statistics. Each new incident cohort
of BC was run through a Markov model reﬂecting the progres-
sion of the disease (silent disease, bone and visceral metastatic
disease, death due to BC, other death). Transition probabilities
for the ﬁrst year of interest were obtained from a recent meta-
analysis on the effect of chemotherapy. Treatments launched
since 1992 were identiﬁed and corresponding risk reductions
(obtained from the literature) applied to the baseline transition
probabilities to reﬂect the improved prognosis of women with
BC. National statistics were used to validate the model.
RESULTS: The use of constant, unadjusted transition probabili-
ties resulted in an over-estimation of the number of BC deaths by
21% in 2005. After adjustment of the transition probabilities to
include recent therapeutic advancements, the model predicted
12,575 BC deaths in 2005, while 12,509 had been observed
(0.53% difference). Assuming that the treatment options remain
unchanged and that BC incidence by age remains constant, the
population of women suffering from BM is predicted to reach
50,000 in 2020. CONCLUSIONS: Modelling the disease pro-
gression at the national level allows the validation of absolute
numbers of patients over time using national statistics. Compari-
son of model predictions with historical data shows that the
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beneﬁt of new treatments for BC is directly measurable at the
national level.
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COST OF INITIAL PROSTATE CANCERTREATMENT
FOLLOWING DIAGNOSIS PER PATIENT BY STAGE:
ESTIMATES FROMTHE UK, FRANCE, GERMANY, ITALY
AND SPAIN
Benedict Á1, Black L2, Stokes ME3
1United BioSource Corporation, Budapest, Hungary, 2GlaxoSmithKline,
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OBJECTIVES: To calculate the total per patient cost of prostate
cancer (PCa) treatment by stage in the 1st year following diagno-
sis in 5 European countries. METHODS: IMS Oncology
Analyzer (OA), a survey-based data collected from urologists,
radiologists, and oncologists between 2002–2006 provided data
on diagnostic interventions and initial treatment for 10,576
patients treated in hospitals for UK, Germany, France, Italy and
Spain. A costing model combined the data with local expert
opinion and published data on resource use and unit costs from
published sources to calculate total per patient costs by stage.
Diagnostic costs, ﬁrst surgery, radio- and chemotherapy costs, if
any, were included. Cost of 1st-line hormonal therapy, with pos-
sibly was also included. Relapse and mortality was factored
into the model. Total direct medical costs of initial treatments
following diagnosis per patient were calculated for all stages.
RESULTS: Majority of men across countries were diagnosed in
Stage II. As initial treatment following diagnosis, across all
stages, radiation therapy (EBT + brachytherapy) was used most
frequently across countries, ranging from 42% (France) to
21.5% (Germany). Use of chemotherapy was low. Total per
patient direct costs following diagnosis averaging all stages were
€4057, €3256 €3171 (exchange rate conversion), €5226 and
€5851 for Germany, Spain, UK, Italy and France, respectively.
Surgeries were the largest cost component in all countries except
for the UK and Germany. In Germany hormone therapy repre-
sents a similar cost to surgery; in the UK where radiation therapy
had the highest cost proportion. CONCLUSIONS: In this ﬁrst
study quantifying the cost of PCa treatment in ﬁve European
countries using similar methods and source across countries
found similar total per patient cost estimates, although different
treatment patterns and types of costs by country. Given the
number of new cases diagnosed in Europe, these estimates
suggest a large total spending on the disease.
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YEARS OF POTENTIAL LIFE LOST AND PRODUCTIVITY
COSTS DUETO CANCER MORTALITY AND FOR SPECIFIC
CANCER SITES WHERE HPV MAY BE A RISK FACTOR FOR
CARCINOGENESIS—UNITED STATES, 2003
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OBJECTIVES: Although years of potential life lost (YPLL) and
mortality-related productivity costs comprise a substantial
portion of the burden of cancers where HPV may be a risk factor
for carcinogenesis (henceforth called HPV-associated cancers),
estimates of these costs are limited. We estimated the mortality-
related burden (in terms of YPLL and productivity costs) of
HPV-associated cancers and all malignant cancers in the United
States in 2003. METHODS: We used 2003 national mortality
data and US life tables to estimate YPLL for HPV-associated
cancers and all malignant cancers. YPLL was estimated by use of
the life expectancy method. We used the human capital approach
to estimate the value of the expected future lifetime productivity
losses due to premature deaths from HPV-associated cancers and
all malignant cancers. Indirect mortality costs were estimated
as the product of the number of deaths and the expected value
of individuals’ future earnings, including an imputed value
of housekeeping services. RESULTS: In 2003, HPV-associated
cancers accounted for 181,026 in YPLL, which represent 2.4%
of the estimated 7.5 million YPLL attributable to all malignant
cancers in the United States. The average number of YPLL was
21.8 per HPV-associated cancer death and 16.3 per death to
overall malignant cancers. Overall, HPV-associated cancers had
the largest relative contribution to YPLL in 30–34 year-old
females. The lifetime productivity cost due to mortality in 2003
was $3.7 billion for HPV-associated cancer mortality and $133.5
billion for overall malignant cancer mortality. CONCLUSIONS:
HPV-associated cancers impose a considerable burden in terms
of premature deaths and productivity losses. Quantifying the
burden of these HPV-associated cancers mortality in the popu-
lation may provide useful information for understanding the full
potential beneﬁts of prevention efforts.
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COST EFFECTIVENESS ANALYSIS OF REYATAZ®VERSUS
KALETRA® INTHETREATMENT OF NAÏVE HIV PATIENTS
IN ITALY
Thuresson PO1, Heeg B1, Neubauer AS2, Intorcia M3,Van Hout BA1
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OBJECTIVES: To estimate the cost-effectiveness of Reyataz®
versus Kaletra® in treatment-naïve HIV-1 patients in Italy.
METHODS: For this purpose a life time Markov model was
developed with a cycle length of one year. The model included the
following health states; 1st, 2nd and 3rd line treatment and within
these treatment lines patients could suffer from an MI, stroke or
angina. Treatment switch transition probabilities were derived
from a 48 week randomized trial and event probabilities were
derived from the Framingham risk equations and the 48 week
trial. Diarrhea was included as a disutility. Variables that differed
between the two treatment arms were pharmaceutical treatment
costs, lipid proﬁle, probability to switch 1st line treatment, mor-
tality and incidence of diarrhea. The analysis was conducted
from a third-party payer perspective. Direct costs inside the
health care system were included. Outcomes were reported as
cost per (quality adjusted) life year gained. To determine the
robustness of the model and the impact of uncertainty, uni- and
multivariate sensitivity analyses were carried out. RESULTS: In
the base case analysis Reyataz® saved 0.07 [-0.50, 0,83] life
years, 0.12 [-0.31, 0.85] QALYs and -€508 [-€88,264, €19,424]
costs. The resulting ICER and ICUR were dominant for
Reyataz®, e.g. cost saving and more effective. Probabilistic sen-
sitivity analyses showed that Reyataz® has 0.80%, 16.70%,
10.30% and a 72.20% probability to be in NW, SW, NE and SE
quadrant of cost-effective scatter plot respectively, and a 94.1%
probability to be cost-effective at a WTP of €20,000. The univari-
ate sensitivity analysis showed that the results were especially
sensitive to changes in the cost of second and third line treatment
and switching treatment probabilities. CONCLUSIONS: The
present model suggests that Reyataz® has a favourable cost-
effective ratio in the treatment of treatment naïve HIV-I patients.
Sensitivity analysis showed that these results were stable.
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